The complete reference for growth hormone-releasing hormone analogues — sermorelin, CJC-1295, and tesamorelin. Mechanism, half-life comparison, FDA status, dosing protocols, and stacking strategies.
Growth hormone-releasing hormone (GHRH) is a 44-amino acid peptide produced by the hypothalamus that stimulates the anterior pituitary to synthesize and secrete growth hormone (GH). It is the primary upstream regulator of the GH/IGF-1 axis, acting in concert with somatostatin (which inhibits GH release) to produce the characteristic pulsatile GH secretion pattern observed in healthy individuals.
GHRH analogues are synthetic peptides designed to mimic or improve upon endogenous GHRH. The key engineering challenge is extending the extremely short half-life of native GHRH (~7 minutes in plasma) while preserving receptor selectivity. Each approved or investigational analogue takes a different structural approach to this problem, resulting in meaningfully different pharmacokinetic profiles and clinical applications.
All GHRH analogues bind the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This G-protein coupled receptor activates adenylyl cyclase, increasing intracellular cAMP.
Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including Pit-1, stimulating GH gene transcription and triggering exocytosis of stored GH granules.
Released GH travels to the liver and peripheral tissues, stimulating IGF-1 production. IGF-1 mediates most of GH's anabolic effects — muscle protein synthesis, lipolysis, and bone mineralization.
Unlike exogenous HGH, GHRH analogues preserve the somatostatin-mediated negative feedback loop. This prevents supraphysiological GH levels and maintains pituitary sensitivity over time.
| Parameter | Sermorelin | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Structure | GHRH(1-29) | GHRH(1-29) + DAC modification | GHRH(1-44) + N-terminal hexenoic acid |
| Half-life | ~11 minutes | ~8 days (with DAC) | ~26 minutes |
| GH release pattern | Pulsatile (physiological) | Sustained blunted pulse | Pulsatile (stronger than sermorelin) |
| Standard dose | 200–500 mcg/day | 1–2 mg/week | 2 mg/day |
| FDA approval | Withdrawn 2008 | None | Yes (2010, HIV lipodystrophy) |
| Best for fat loss | Moderate | Good | Excellent (Phase III evidence) |
| Best for anti-aging/sleep | Excellent | Good | Good |
| Best for muscle growth | Moderate | Good | Moderate |
| IGF-1 elevation | Moderate (+30–50%) | High (+50–100%) | High (+60–80%) |
| Injection frequency | Daily | 1–2×/week | Daily |
GHRH analogues should not be stacked with each other — they compete for the same GHRHR receptor and provide no additive benefit. The most effective stacking strategy is to pair a GHRH analogue with a growth hormone-releasing peptide (GHRP), which acts on the separate ghrelin receptor (GHS-R1a) and amplifies GH pulse magnitude through a complementary mechanism.
Dosing: Sermorelin 200–300 mcg + Ipamorelin 100–200 mcg, evening SQ
Best for: Anti-aging, sleep quality, physiological GH restoration
Dosing: CJC-1295 1 mg 2×/week + Ipamorelin 100–200 mcg daily
Best for: Muscle growth, sustained IGF-1 elevation, body recomposition
Dosing: Tesamorelin 1–2 mg daily + Ipamorelin 100 mcg, evening SQ
Best for: Visceral fat reduction, body composition, metabolic improvement
Half-life, FDA approval, visceral fat evidence, and decision matrix
DAC modification, potency comparison, and stacking rationale
GHRH vs GHRP: mechanism differences and combination protocols
Three-way GHRH analogue comparison — the definitive guide
A GHRH analogue is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the pituitary to produce and release growth hormone. Unlike exogenous HGH, GHRH analogues work upstream — they stimulate the body's own GH production rather than replacing it.
GHRH analogues (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor and stimulate GH synthesis and release via the cAMP pathway. GHRPs (growth hormone-releasing peptides) such as ipamorelin and GHRP-6 bind the ghrelin receptor (GHS-R1a) and amplify GH release via a different pathway. The two classes are synergistic and are commonly stacked.
Tesamorelin has the strongest clinical evidence for visceral fat reduction — it is the only GHRH analogue with FDA approval for this indication, with Phase III trials showing 15–18% VAT reduction over 26 weeks. CJC-1295 also shows fat loss effects due to sustained GH elevation. Sermorelin has less direct fat loss evidence but contributes to improved body composition over longer cycles.
Sermorelin is the most commonly used GHRH analogue for anti-aging and sleep quality improvement. Its pulsatile, physiological GH stimulation closely mimics youthful GH secretion patterns. Evening administration before sleep synchronizes with the natural GH pulse that occurs during slow-wave sleep.
GHRH analogues should not be stacked with each other (e.g., sermorelin + CJC-1295) as they compete for the same receptor. The most effective stacking strategy is to combine a GHRH analogue with a GHRP such as ipamorelin, which acts on a different receptor and amplifies the GH pulse via a complementary mechanism.
Purgo Labs provides pharmaceutical-grade GHRH analogue peptides with third-party COA verification, ≥99% purity, and cGMP manufacturing standards. Use code HEALTH for 15% off.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.